Author

Geert R. D'Haens

CLINICAL AND ENDOSCOPIC IMPROVEMENTS WITH RISANKIZUMAB INDUCTION AND MAINTENANCE DOSING VERSUS PLACEBO ARE OBSERVED IRRESPECTIVE OF NUMBER OF PRIOR FAILED BIOLOGICS
CLINICAL AND ENDOSCOPIC IMPROVEMENTS WITH RISANKIZUMAB INDUCTION AND MAINTENANCE DOSING VERSUS PLACEBO ARE OBSERVED IRRESPECTIVE OF NUMBER OF PRIOR FAILED BIOLOGICS

Geert R. D'Haens  et al.

EFFICACY OUTCOMES BY SYMPTOM-BASED RESPONSE STATUS AFTER INDUCTION: WEEK-48 RESULTS FROM THE GALAXI 1 TRIAL OF GUSELKUMAB IN CROHN’S DISEASE
EFFICACY OUTCOMES BY SYMPTOM-BASED RESPONSE STATUS AFTER INDUCTION: WEEK-48 RESULTS FROM THE GALAXI 1 TRIAL OF GUSELKUMAB IN CROHN’S DISEASE

Geert R. D'Haens  et al.

REAL WORLD CLINICAL AND ENDOSCOPIC OUTCOMES AFTER ONE YEAR TOFACITINIB TREATMENT IN ULCERATIVE COLITIS
REAL WORLD CLINICAL AND ENDOSCOPIC OUTCOMES AFTER ONE YEAR TOFACITINIB TREATMENT IN ULCERATIVE COLITIS

Geert R. D'Haens  et al.

THE DIAGNOSTIC PERFORMANCE OF A TRAINED PHYSICIAN VS. A PEDIATRIC RADIOLOGIST IN PERFORMING AN INTESTINAL ULTRASOUND IN CHILDREN WITH IBD
THE DIAGNOSTIC PERFORMANCE OF A TRAINED PHYSICIAN VS. A PEDIATRIC RADIOLOGIST IN PERFORMING AN INTESTINAL ULTRASOUND IN CHILDREN WITH IBD

Geert R. D'Haens  et al.

HEAD-TO-HEAD PHARMACOKINETIC ANALYSIS OF INFLIXIMAB MONO- VS COMBINATION THERAPY IN PAEDIATRIC CROHN’S DISEASE
HEAD-TO-HEAD PHARMACOKINETIC ANALYSIS OF INFLIXIMAB MONO- VS COMBINATION THERAPY IN PAEDIATRIC CROHN’S DISEASE

Geert R. D'Haens  et al.

A TRANSCRIPTOME-DEPENDENT PROGNOSTIC MODEL OF RESPONSE IN PATIENTS WITH ULCERATIVE COLITIS
A TRANSCRIPTOME-DEPENDENT PROGNOSTIC MODEL OF RESPONSE IN PATIENTS WITH ULCERATIVE COLITIS

Geert R. D'Haens  et al.

EFFICACY AND SAFETY OF MIRIKIZUMAB AFTER 52-WEEKS MAINTENANCE TREATMENT IN PATIENTS WITH MODERATE-TO-SEVERE CROHN'S DISEASE
EFFICACY AND SAFETY OF MIRIKIZUMAB AFTER 52-WEEKS MAINTENANCE TREATMENT IN PATIENTS WITH MODERATE-TO-SEVERE CROHN'S DISEASE

Geert R. D'Haens  et al.

THE EFFICACY AND SAFETY OF GUSELKUMAB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: WEEK 12 INTERIM ANALYSES FROM THE PHASE 2 GALAXI 1 STUDY
THE EFFICACY AND SAFETY OF GUSELKUMAB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: WEEK 12 INTERIM ANALYSES FROM THE PHASE 2 GALAXI 1 STUDY

Geert R. D'Haens  et al.

INTESTINAL ULTRASOUND IN ULCERATIVE COLITIS PATIENTS TREATED WITH TOFACITINIB PREDICTS ENDOSCOPIC OUTCOMES, A LONGITUDINAL PROSPECTIVE COHORT STUDY
INTESTINAL ULTRASOUND IN ULCERATIVE COLITIS PATIENTS TREATED WITH TOFACITINIB PREDICTS ENDOSCOPIC OUTCOMES, A LONGITUDINAL PROSPECTIVE COHORT STUDY

Geert R. D'Haens  et al.

IMPACT OF 8 WEEKS TOFACITINIB TREATMENT ON HISTOLOGICAL INFLAMMATION IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS
IMPACT OF 8 WEEKS TOFACITINIB TREATMENT ON HISTOLOGICAL INFLAMMATION IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS

Geert R. D'Haens  et al.

PERIPHERAL BLOOD DNA METHYLATION PROFILES PREDICT RESPONSE TO USTEKINUMAB AND SHOW STABILITY DURING BOTH INDUCTION AND MAINTENANCE TREATMENT IN CROHN’S DISEASE
PERIPHERAL BLOOD DNA METHYLATION PROFILES PREDICT RESPONSE TO USTEKINUMAB AND SHOW STABILITY DURING BOTH INDUCTION AND MAINTENANCE TREATMENT IN CROHN’S DISEASE

Geert R. D'Haens  et al.

THE EFFECT OF MIRIKIZUMAB ON FECAL CALPROTECTIN AND C-REACTIVE PROTEIN IN PHASE 3 STUDIES OF PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
THE EFFECT OF MIRIKIZUMAB ON FECAL CALPROTECTIN AND C-REACTIVE PROTEIN IN PHASE 3 STUDIES OF PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

Geert R. D'Haens  et al.

EFFICACY OF UPADACITINIB DOSE ESCALATION IN A PHASE 3 LONG-TERM EXTENSION ULCERATIVE COLITIS STUDY
EFFICACY OF UPADACITINIB DOSE ESCALATION IN A PHASE 3 LONG-TERM EXTENSION ULCERATIVE COLITIS STUDY

Geert R. D'Haens  et al.

EFFECTS OF OZANIMOD ON CIRCULATING LYMPHOCYTES IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: FLOW CYTOMETRY RESULTS FROM THE STEPSTONE PHASE 2 STUDY
EFFECTS OF OZANIMOD ON CIRCULATING LYMPHOCYTES IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: FLOW CYTOMETRY RESULTS FROM THE STEPSTONE PHASE 2 STUDY

Geert R. D'Haens  et al.

EFFICACY AND SAFETY OF ETRASIMOD IN PATIENTS WITH MODERATE TO SEVERE ISOLATED PROCTITIS RELATIVE TO THOSE WITH MORE EXTENSIVE COLITIS: RESULTS FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS
EFFICACY AND SAFETY OF ETRASIMOD IN PATIENTS WITH MODERATE TO SEVERE ISOLATED PROCTITIS RELATIVE TO THOSE WITH MORE EXTENSIVE COLITIS: RESULTS FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS

Geert R. D'Haens  et al.

A SINGLE-CELL RNA SEQUENCING ATLAS OF THE TUMOR ENVIRONMENT IN PERITONEAL METASTASIZED COLORECTAL CANCER IDENTIFIES ANTI-INFLAMMATORY MACROPHAGES AS POTENTIAL TARGETS FOR THERAPY
A SINGLE-CELL RNA SEQUENCING ATLAS OF THE TUMOR ENVIRONMENT IN PERITONEAL METASTASIZED COLORECTAL CANCER IDENTIFIES ANTI-INFLAMMATORY MACROPHAGES AS POTENTIAL TARGETS FOR THERAPY

Geert R. D'Haens  et al.

CHARACTERIZATION OF CYTOKINE AND DRUG CONCENTRATIONS IN SERUM, MUCOSA AND FAECES DURING INDUCTION TREATMENT OF SEVERE ULCERATIVE COLITIS WITH INFLIXIMAB
CHARACTERIZATION OF CYTOKINE AND DRUG CONCENTRATIONS IN SERUM, MUCOSA AND FAECES DURING INDUCTION TREATMENT OF SEVERE ULCERATIVE COLITIS WITH INFLIXIMAB

Geert R. D'Haens  et al.

MUCOSAL B-CELL EXPANSION AND MATURATION CONTRIBUTE TO ULCERATIVE COLITIS PATHOGENESIS
MUCOSAL B-CELL EXPANSION AND MATURATION CONTRIBUTE TO ULCERATIVE COLITIS PATHOGENESIS

Geert R. D'Haens  et al.

CONTRAST-ENHANCED ULTRASOUND DISTINGUISHES INFLAMMATORY FROM NON-INFLAMMATORY STENOSIS IN CROHN’S DISEASE: FIRST RESULTS FROM THE STRICTURE STUDY
CONTRAST-ENHANCED ULTRASOUND DISTINGUISHES INFLAMMATORY FROM NON-INFLAMMATORY STENOSIS IN CROHN’S DISEASE: FIRST RESULTS FROM THE STRICTURE STUDY

Geert R. D'Haens  et al.

MUCOSA-ASSOCIATED MICROBIAL SIGNATURES DISCRIMINATE RESPONSE TO BIOLOGICALS IN CROHN’S DISEASE
MUCOSA-ASSOCIATED MICROBIAL SIGNATURES DISCRIMINATE RESPONSE TO BIOLOGICALS IN CROHN’S DISEASE

Geert R. D'Haens  et al.

Item 61 - 80 / 98
1 2 3
4
5